REG - GSK PLC - Director/PDMR Shareholding

GSKAnnouncement

15/05/2023 15:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230515:nRSO4636Za&default-theme=true

RNS Number : 4636Z  GSK PLC  15 May 2023

GSK plc (the 'Company')

Vesting of 2020 Performance Share Plan Top-Up Award

This notification sets out the vesting details of a "top-up" conditional share
award made to the Chief Executive Officer (CEO) on 6 May 2020 under the GSK
2017 Performance Share Plan ('PSP'), following the approval of the 2020
Remuneration Policy at the AGM that year.

This "top-up" PSP award, equivalent to 25% of the CEO's base salary, was made
to deliver in aggregate for 2020 an award level of 575% of base salary,
increasing her award level from 550%. It was subject to the same business
performance conditions as the main 2020 award, with a three-year performance
period from 1 January 2020 to 31 December 2022.  The main 2020 award vesting
was announced on 14 February 2023
(https://otp.tools.investis.com/clients/uk/gsk/rns/regulatory-story.aspx?cid=410&newsid=1667982)
.  The "top-up" award has now vested on the same basis ie 52% vesting 48%
lapsed, following the third anniversary of the grant. The vested shares are
subject to a further two-year vesting period.

This notification that follows is for the "top-up" award made to the CEO and
details the PSP conditional award that vested, including dividends accrued, on
9 May 2023.  The balance of the award has lapsed.

The closing price of Ordinary Shares of GSK plc on the vesting date was
£14.462.

Transaction notification

 

 1.  Details of PDMR/person closely associated with them ('PCA')
 a)  Name                                     Ms E Walmsley
 b)  Position/status                          Chief Executive Officer
 c)  Initial notification/                    Initial notification

     amendment
 2.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                     GSK plc
 b)  LEI                                      5493000HZTVUYLO1D793
 3.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transaction(s) has been conducted
 a)  Description of the financial instrument  Ordinary Shares of 31 ¼ pence each ('Ordinary Shares')

                                              ISIN: GB00BN7SWP63
 b)  Nature of the transaction                The number of Ordinary Shares vesting on the "top-up" award granted in 2020
                                              under the Company's 2017 Performance Share Plan
 c)  Price(s) and volume(s)                                        Price(s)             Volume(s)
                                                                   £0.00                10,729

 d)  Aggregated information                   N/A (single transaction)

     Aggregated volume Price
 e)  Date of the transaction                  2023-05-09
 f)  Place of the transaction                 N/A

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHSFUFLIEDSESI